EP4380588A4 - Psychoactive drugs and their use in the treatment of psychiatric and neurological diseases and disorders - Google Patents

Psychoactive drugs and their use in the treatment of psychiatric and neurological diseases and disorders

Info

Publication number
EP4380588A4
EP4380588A4 EP22854040.7A EP22854040A EP4380588A4 EP 4380588 A4 EP4380588 A4 EP 4380588A4 EP 22854040 A EP22854040 A EP 22854040A EP 4380588 A4 EP4380588 A4 EP 4380588A4
Authority
EP
European Patent Office
Prior art keywords
psychiatric
disorders
treatment
neurological diseases
psychoactive drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22854040.7A
Other languages
German (de)
French (fr)
Other versions
EP4380588A1 (en
Inventor
Blake Mandell
Martin Stogniew
Jennifer Louise Schmidt
Markus Seelig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Publication of EP4380588A1 publication Critical patent/EP4380588A1/en
Publication of EP4380588A4 publication Critical patent/EP4380588A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP22854040.7A 2021-08-06 2022-08-01 Psychoactive drugs and their use in the treatment of psychiatric and neurological diseases and disorders Pending EP4380588A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163230237P 2021-08-06 2021-08-06
US202163240113P 2021-09-02 2021-09-02
US202163255706P 2021-10-14 2021-10-14
US202263325757P 2022-03-31 2022-03-31
US202263328343P 2022-04-07 2022-04-07
PCT/US2022/074369 WO2023015154A1 (en) 2021-08-06 2022-08-01 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (2)

Publication Number Publication Date
EP4380588A1 EP4380588A1 (en) 2024-06-12
EP4380588A4 true EP4380588A4 (en) 2025-10-08

Family

ID=85156410

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22854040.7A Pending EP4380588A4 (en) 2021-08-06 2022-08-01 Psychoactive drugs and their use in the treatment of psychiatric and neurological diseases and disorders

Country Status (10)

Country Link
US (6) US11707446B2 (en)
EP (1) EP4380588A4 (en)
JP (1) JP2024530007A (en)
KR (1) KR20240072133A (en)
AU (1) AU2022325135A1 (en)
CA (1) CA3227360A1 (en)
IL (1) IL310334A (en)
MX (1) MX2024001654A (en)
TW (1) TW202327571A (en)
WO (1) WO2023015154A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254190A2 (en) * 2023-06-06 2024-12-12 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12295937B2 (en) 2021-08-06 2025-05-13 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US12343326B2 (en) 2021-08-06 2025-07-01 Transcend Therapeutics, Inc. Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
MX2024001654A (en) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders.
KR20240165982A (en) * 2022-03-31 2024-11-25 트랜센드 테라퓨틱스 인코퍼레이티드 Psychotropic drugs and their use in the treatment of mental and nervous system conditions and disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
WO2022212854A1 (en) * 2021-04-01 2022-10-06 Terran Biosciences Inc. Methods and compositions relating to psychedelics and serotonin receptor modulators
WO2023081403A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences Inc. Isotopologes, salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575194B1 (en) 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
MX2024001654A (en) 2021-08-06 2024-06-28 Transcend Therapeutics Inc Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
WO2022212854A1 (en) * 2021-04-01 2022-10-06 Terran Biosciences Inc. Methods and compositions relating to psychedelics and serotonin receptor modulators
WO2023081403A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences Inc. Isotopologes, salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAHJI ANEES ET AL: "Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, ELSEVIER, GB, vol. 96, 19 August 2019 (2019-08-19), XP085883034, ISSN: 0278-5846, [retrieved on 20190819], DOI: 10.1016/J.PNPBP.2019.109735 *
KARILA LAURENT ET AL: "The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences", BRAIN RESEARCH BULLETIN, ELSEVIER SCIENCE LTD, OXFORD, GB, vol. 126, 16 March 2016 (2016-03-16), pages 61 - 67, XP029753108, ISSN: 0361-9230, DOI: 10.1016/J.BRAINRESBULL.2016.03.005 *
OERI HANS EMANUEL: "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy", JOURNAL OF PSYCHOPHARMACOLOGY., vol. 35, no. 5, 10 September 2020 (2020-09-10), GB, pages 512 - 536, XP093004528, ISSN: 0269-8811, DOI: 10.1177/0269881120920420 *
See also references of WO2023015154A1 *

Also Published As

Publication number Publication date
US20240058301A1 (en) 2024-02-22
WO2023015154A1 (en) 2023-02-09
US20240293357A1 (en) 2024-09-05
EP4380588A1 (en) 2024-06-12
US11969407B2 (en) 2024-04-30
US20230054211A1 (en) 2023-02-23
TW202327571A (en) 2023-07-16
US12059402B2 (en) 2024-08-13
US20250255846A1 (en) 2025-08-14
CA3227360A1 (en) 2023-02-09
KR20240072133A (en) 2024-05-23
US11707446B2 (en) 2023-07-25
JP2024530007A (en) 2024-08-14
US12233046B2 (en) 2025-02-25
IL310334A (en) 2024-03-01
US20260083699A1 (en) 2026-03-26
MX2024001654A (en) 2024-06-28
US20230338333A1 (en) 2023-10-26
AU2022325135A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP4380588A4 (en) Psychoactive drugs and their use in the treatment of psychiatric and neurological diseases and disorders
IL288214A (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
DE60319865D1 (en) SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIONESIS-RELATED DISEASES
EP4288048A4 (en) Inspired oxa-ibogaine analogues for the treatment of neurological and psychiatric disorders
DE602005015451D1 (en) COMPOSITION BASED ON PROBIOTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR TREATMENT OF RESPIRATORY DISEASES AND / OR INFECTIONS AND FOR IMPROVING DRUG ACTIVITY
PL3956310T3 (en) <div>MODIFIED AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND SELECTED MENTAL DISORDERS</div>
IL287748A (en) Treatment and detection of hereditary neurological diseases and related disorders
EP3581175A4 (en) MEDICINAL DELIVERY FORMULATION FOR THE TREATMENT OF MENTAL DISEASES OR CENTRAL NERVOUS SYSTEM DISORDERS
EP4359405A4 (en) BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES
IL309317A (en) Treatment of mtres1 related diseases and disorders
EP4196127C0 (en) NICOTINAMIDE MONONUCLEOIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF SICKLE CELL DISEASE
ATE456955T1 (en) USE OF CYCLODEXTRIN TO TREAT AND PREVENT BRONCHIAL INFLAMMATORY DISEASE
EP4288075A4 (en) SELECTIVE ROCK2 INHIBITION FOR THE TREATMENT OF EDEMA AND RELATED DISEASES
EP4549459A4 (en) AAV drug for the treatment of angiogenesis-related fundus diseases
EP4093389A4 (en) PRODRUG FOR THE TREATMENT OF DISEASES AND INJURIES OF OXIDATIVE STRESS
DE60312505D1 (en) INJECTION FROM IXERIS SONCHIFOLIA FOR THE TREATMENT OF CARDIOZEREBRAL VASCULAR DISEASES AND FUNDUS DISEASES AND METHOD OF PRODUCTION THEREOF
EP4499066A4 (en) Psychoactive drugs and their use in the treatment of psychiatric and neurological diseases and disorders
EP4215531A4 (en) COMPOUND FOR THE PREVENTION AND TREATMENT OF LIVER DISEASES AND PHARMACEUTICAL USE THEREOF
EP4527387A4 (en) Pharmaceutical compound for the treatment of glaucoma and use thereof
EP3881849C0 (en) COMPOSITION WITH APTAMER AS ACTIVE INGREDIENT FOR THE TREATMENT AND PREVENTION OF DEGENERATIVE BRAIN DISEASES
IL313904A (en) Heterocyclic derivatives and their use in the treatment of central nervous system disorders
EP4522772A4 (en) TREATMENT OF DISEASES AND DISORDERS WITH IRAK4-MODIFIING COMPOUNDS
EP4410296A4 (en) DIRECT TRANSDIFFERENTIATION FOR THE TREATMENT OF NEUROLOGICAL DISEASES
EP4467140A4 (en) PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS AND USE OF IT

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40112016

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0036185000

Ipc: A61K0031360000

A4 Supplementary search report drawn up and despatched

Effective date: 20250910

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/36 20060101AFI20250904BHEP

Ipc: A61K 36/185 20060101ALI20250904BHEP

Ipc: A61K 45/06 20060101ALI20250904BHEP

Ipc: A61P 25/22 20060101ALI20250904BHEP

Ipc: A61P 25/24 20060101ALI20250904BHEP